Delivery Order SPE2DR25D1053-SPE2DR26FT113
- Not listed
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 29, 2025, for the supply of Venclexta 100 mg tablets (120 count) valued at $9,728.17. This competitively awarded, firm fixed-price delivery order is set to conclude by October 21, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 2, 2025, for the supply of Venclexta 100 mg tablets (120 count) at a ceiling value of $9,728.17. This is a firm fixed-price delivery order with no set-aside designation, representing a competitively awarded contract. The order is set for ultimate completion by May 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Venclexta 100 mg tablets (120 count) with a ceiling value of $9,728.17. This is a firm fixed price delivery order with no set-aside designation, issued under competitive procedures. The order is scheduled for completion by October 9, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Venclexta 100 mg tablets (120-count units) with a contract ceiling value of $9,728.17. This is a firm fixed-price delivery order with an ultimate completion date of August 15, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Venclexta 100 mg tablets (120-count units) valued at $9,728.17, with an ultimate completion date of October 8, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of Venclexta 100 mg tablets (120-count units) valued at $9,728.17, with completion scheduled for October 15, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Venclexta 100 mg tablets (quantity: 120 tablets) with a ceiling value of $116,738.04. This competitively awarded, firm fixed-price delivery order is scheduled for completion by October 20, 2025, and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The contract contains no set-aside designation, reflecting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Venclexta 50 mg tablet unit dose packages (quantity 7). This non-set-aside, competitively awarded contract is valued at $1,743.06 with a firm fixed price and is scheduled for completion by September 4, 2025. The order will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $2,289.70 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Venclexta 100 mg tablets (28-count unit dosage). This non-set-aside competitive award is scheduled for completion by September 30, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,728.17 to AmerisourceBergen Drug Corp for 120 tablets of Venclexta 100 mg on September 10, 2025, with completion targeted for October 1, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $1 billion through December 2026. The...
- SPE2DR25D1053Indefinite Delivery Contract
- SPE2DR25D1053-SPE2DR26FT113Delivery Order
The Defense Logistics Agency awarded a $10,251.99 delivery order to AmerisourceBergen Drug Corp on October 20, 2025, for the supply of Venclexta 100 mg tablets (120-count units). This competitively awarded, firm fixed-price delivery order is scheduled for completion by November 10, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger pharmaceutical supply vehicle with the DLA. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical procurement, holds a substantial Indefinite Delivery Contract with DLA Troop Support Medical valued at $999,999,999.00 through December 2026. This prime contract vehicle, designated SPE2DX, enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The current delivery order for Venclexta, an oncology medication, exemplifies the company's role in supplying specialized brand-name pharmaceuticals to support Defense Health Agency and broader military healthcare operations across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.3k | 10/20/25 |